aTyr Pharma, Inc. (NASDAQ: ATYR) has garnered a consensus recommendation of “Hold” from analysts following the stock. According to a report from MarketBeat, out of seven analysts currently covering the company, one has issued a sell rating, five have recommended holding the stock, and one has given it a buy rating. The average price target over the next 12 months stands at approximately $25.67.
Several brokerage firms have recently provided updates on aTyr Pharma. Notably, Jefferies Financial Group reaffirmed a “buy” rating in a report released on March 5, 2024. Conversely, Weiss Ratings maintained a “sell (d-)” rating in a report on December 29, 2023.
During mid-day trading on Friday, aTyr Pharma’s stock experienced a decline of 8.7%, falling $0.08 to a price of $0.82. The trading volume reached 1,749,790 shares, exceeding the average volume of 1,496,836. Over the past year, the stock has fluctuated between a low of $0.64 and a high of $7.29. The company’s fifty-day moving average is currently $0.84, while the 200-day moving average stands at $1.43. aTyr Pharma has a market capitalization of $80.74 million and a price-to-earnings ratio of -1.04.
Based in San Diego, California, aTyr Pharma, Inc. is a clinical-stage biotechnology firm that focuses on developing innovative protein-based therapies. The company utilizes its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates aimed at treating rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors. Its research primarily concentrates on using extracellular proteins to influence tissue remodeling, cell adhesion, and immune signaling.
As the market continues to react to various reports, investors and analysts will be closely monitoring aTyr Pharma’s performance in the coming months.
